Depot fluphenazine decanoate and enanthate for schizophrenia (Q24247121)

ChEBI release 2020-05-28

1 reference

Clive E Adams

2

0 references

author name string

Anthony David

1

0 references

Maurice Eisenbruch

3

0 references

Seema N Quraishi

4

0 references

John Rathbone

5

0 references

A David

1

0 references

C E Adams

2

0 references

M Eisenbruch

3

0 references

S Quraishi

4

0 references

J Rathbone

Cochrane Database of Systematic Reviews

5

0 references

language of work or name

English

0 references

publication date

19 April 2004

0 references

25 January 2005

0 references

published in

0 references

page(s)

CD000307

0 references

issue

1

0 references

cites work

Differential effect of low and conventional doses of fluphenazine on schizophrenic outpatients with good or poor information-processing abilities

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000307

Depot Phenothiazine Treatment in Acute Psychosis: A Sequential Comparative Clinical Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000307

Fluphenazine enanthate and fluphenazine decanoate in the treatment of schizophrenic outpatients: extrapyramidal symptoms and therapeutic effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000307

How schizophrenic patients change during 3 years' treatment with depot neuroleptics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000307

Three years' maintenance neuroleptic treatment in schizophrenia ? before and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000307

Medico-social evaluation of the long-term pharmacotherapy of schizophrenia. Comparative study of fluphenazine and pimozide

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000307

Double-blind therapeutic evaluation of fluspirilene compared with fluphenazine decanoate in chronic schizophrenics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000307

Drug and Family Therapy in the Aftercare of Acute Schizophrenics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000307

Fluphenazine and social therapy in the aftercare of schizophrenic patients. Relapse analyses of a two-year controlled study of fluphenazine decanoate and fluphenazine hydrochloride

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000307

Dose of fluphenazine, familial expressed emotion, and outcome in schizophrenia. Results of a two-year controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000307

Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical and social outcome at two years

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000307

Double-blind comparison of haloperidol decanoate and fluphenazine decanoate effectiveness, side-effects, dosage and serum levels during a six months' treatment for relapse prevention.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000307

Costs and benefits of two doses of fluphenazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000307

Very high dose fluphenazine decanoate: a controlled trial in chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000307

A double-blind comparison of flupenthixol decanoate and fluphenazine decanoate in the treatment of chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000307

Long-acting oral vs injectable antipsychotic drugs in schizophrenics: a one-year double-blind comparison in multiple episode schizophrenics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000307

Fluphenazine decanoate, fluphenazine hydrochloride given orally, and placebo in remitted schizophrenics. I. Relapse rates after one year

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000307

Acute extrapyramidal reactions with fluphenazine hydrochloride and fluphenazine decanoate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000307

Development and Prediction of Postpsychotic Depression in Neuroleptic-Treated Schizophrenics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000307

Prevention of relapse in schizophrenia. An evaluation of fluphenazine decanoate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000307

Standard and long-acting depot neuroleptics in chronic schizophrenics: an 18-month open multicentric study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000307

Fluphenazine Enanthate and Fluphenazine Decanoate: A Comparison of Their Duration of Action and Motor Side Effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000307

Neuroleptic responsivity of negative and positive symptoms in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000307

Clinical and work performance variables in phenothiazine therapy of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000307

Antiparkinsonian agents and depot phenothiazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000307

Drug Treatment in Newly Admitted Schizophrenic Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000307

High doses of fluphenazine enanthate in schizophrenia: A CONTROLLED STUDY

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000307

Depression and the reintegration phase of acute schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000307

A double-blind comparison of fluphenazine and haloperidol in outpatient schizophrenic children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000307

Comparison of Haloperidol and Fluphenazine in Disturbed Children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000307

A Clinical Evaluation of Prolixin Enanthate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000307

A comparative trial of the decanoates of flupenthixol and fluphenazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000307

Work performance versus clinical assessment in the evaluation of phenothiazine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000307

A comparative trail of fluphenazine decanoate and flupenthixol decanoate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000307

Pharmacotherapy of impaired affect in recovering schizophrenic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000307

A double-blind dose-reduction trial of fluphenazine decanoate for chronic, unstable schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000307

l-5-Hydroxytryptophan-induced delirium

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000307

Treatment of Resistant Schizophrenics With Extreme High Dosage Fluphenazine Hydrochloride

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000307

Clinical and quantitative EEG changes at different dosage levels of fluphenazine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000307

Low dose fluphenazine decanoate in maintenance treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000307

Therapist Ratings of Achievement of Objectives in Psychotherapy With Acute Schizophrenics*

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000307

A new method of drug therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000307

Fluphenazine treatment of DSM-III-R male schizophrenic patients among the Xhosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000307

Trial of Maintenance Therapy in Schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000307

Fluphenazine plasma levels, dosage, efficacy, and side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000307

Fluphenazine dose, clinical response, and extrapyramidal symptoms during acute treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000307

Quantitative effects of typical and atypical neuroleptics on smooth pursuit eye tracking in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000307

Fluphenazine plasma levels in patients receiving low and conventional doses of fluphenazine decanoate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000307

Two-year outcome of social skills training and group psychotherapy for outpatients with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000307

Effects of clozapine and fluphenazine treatment on responses to m-chlorophenylpiperazine infusions in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000307

Clinical and biologic response to clozapine in patients with schizophrenia. Crossover comparison with fluphenazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000307

A comparison of fluphenazine and chlorpromazine on critical flicker fusion frequency

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000307

Pharmacokinetics of haloperidol and fluphenazine decanoates in chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000307

Long-term depot antipsychotics. A risk-benefit assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000307

Statistics notes. Trials randomised in clusters

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000307

Severe Depressive Mood Changes Following Slow-release Intramuscular Fluphenazine Injection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000307

The unit of analysis error in studies about physicians' patient care behavior

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000307

Issues in the meta-analysis of cluster randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000307

Diagnostic Criteria for Use in Psychiatric Research

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000307

Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000307

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000307

Outpatient maintenance of chronic schizophrenic patients with long-acting fluphenazine: double-blind placebo trial. Report to the Medical Research Council Committee on Clinical Trials in Psychiatry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000307

Schizophrenia: manifestations, incidence and course in different cultures. A World Health Organization ten-country study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000307

A standardized psychiatric assessment scale for rating chronic psychotic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000307

The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000307

Relapse and Rehospitalization During Maintenance Treatment of Schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000307

Guidelines for depot antipsychotic treatment in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000307

Prediction of Improvement in Schizophrenia Under Four Phenothiazines

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000307

7 January 2021

Long-acting phenothiazine (fluphenazine decanoate) treatment of psychosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000307

7 January 2021

Life history and symptoms in schizophrenia. Severity at hospitalization and response to phenothiazines

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000307

7 January 2021

Very high dosage vs standard dosage fluphenazine in schizophrenia. A double-blind study of nonchronic treatment-refractory patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000307

7 January 2021

Fluphenazine vs Placebo in Patients With Remitted, Acute First-Episode Schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000307

7 January 2021

Low-dose neuroleptic treatment of outpatient schizophrenics. I. Preliminary results for relapse rates

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000307

7 January 2021

Low- and conventional-dose maintenance therapy with fluphenazine decanoate. Two-year outcome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000307

7 January 2021

Clinical response to clozapine in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000307

7 January 2021

A preliminary study of the comparative effects of olanzapine and fluphenazine on cognition in schizophrenic patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000307

7 January 2021

Comparative study of the pharmacokinetics of zuclopenthixol decanoate and fluphenazine decanoate

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000307

7 January 2021

EEG changes after fluphenazine enanthate and decanoate based on analog power spectra and digital computer period analysis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000307

7 January 2021

The comparative effectiveness of eight phenothiazines

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000307

7 January 2021

A comparative study of two long acting phenothiazine preparations, fluphenazine-enanthate and fluphenazine-decanoate

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000307

7 January 2021

A depot neuroleptic withdrawal study neurological effects

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000307

7 January 2021

Early unwanted effects of fluphenazine esters related to plasma fluphenazine concentrations in schizophrenic patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000307

7 January 2021

A depot neuroleptic withdrawal study. Plasma concentration of fluphenazine and flupenthixol and relapse frequency

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000307

7 January 2021

Use of the Social Behaviour Assessment Schedule (SBAS) in a trial of maintenance antipsychotic therapy in schizophrenic outpatients: Pimozide versus fluphenazine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000307

7 January 2021

Work study in the assessment of the effects of phenothiazines in schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000307

7 January 2021

Comparison of depot fluphenazines: Duration of action and incidence of side effects

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000307

7 January 2021

Depot fluphenazine and flupenthixol in the treatment of stabilized schizophrenics. A double-blind comparative trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000307

7 January 2021

Effect of phenothiazines on reaction time in schizophrenics

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000307

7 January 2021

Fluphenazine decanoate in acute and maintenance therapy of schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000307

7 January 2021

Maintenance treatment of schizophrenic outpatients with a depot phenothiazine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000307

7 January 2021

Prolixin enanthate and thorazine-stelazine regimens in the treatment of schizophrenic patients. An experimental evaluation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000307

7 January 2021

Prevention of Recidivism of Schizophrenics Treated with Fluphenazine Enanthate

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000307

7 January 2021

Double-blind trial of fluphenazine decanoate

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000307

7 January 2021

A comparative controlled trial of pimozide and fluphenazine decanoate in the continuation therapy of schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000307

7 January 2021

The social outcome of patients in a trial of long-term continuation therapy in schizophrenia: pimozide vs. fluphenazine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000307

7 January 2021

Clinical Blood Chemistry Values and Long Acting Phenothiazines

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000307

7 January 2021

[Drug-response differences of high and standard dosage of fluphenazine-decanoate in relation to schizophrenic symptoms (author's transl)]

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000307

7 January 2021

Family Attitudes and Patient Social Adjustment in a Longitudinal Study of Outpatient Schizophrenics Receiving Low-Dose Neuroleptics: The Family’s View

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000307

7 January 2021

Low Dose Medication Strategies in the Maintenance Treatment of Schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000307

7 January 2021

A controlled comparison of the treatment of schizophrenic patients when treated according to the neurologic threshold or by clinical judgment

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000307

7 January 2021

A multicenter controlled trial of fluspirilene and fluphenazine enanthate in chronic schizophrenic syndromes

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000307

7 January 2021

A study of flupenthixol decanoate and pipotiazine undecylenate in schizophrenics

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000307

7 January 2021

A double-blind comparison of fluphenazine decanoate and flupenthixol decanoate in the treatment of acute schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000307

7 January 2021

A comprehensive psychopathological rating scale

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000307

7 January 2021

A depot neuroleptic withdrawal study. A controlled study of the clinical effects of the withdrawal of depot fluphenazine decanoate and depot flupenthixol decanoate in chronic schizophrenic patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000307

7 January 2021

Comparative double-blind study of flupenthixol decanoate and fluphenazine decanoate in the treatment of patients relapsing in a schizophrenic symptomatology

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000307

7 January 2021

The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000307

7 January 2021

Does short term placebo treatment of chronic schizophrenia produce long term harm?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000307

7 January 2021

Fluphenazine decanoate and fluphenazine enanthate in the out-patient management of chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000307

7 January 2021

The problem of post-psychotic schizophrenic depressions and their pharmacological induction. Long-term studies with fluspirilene and penfluridol and single-blind trial with fluphenazine-decanoate and flupenthixol-decanoate

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000307

7 January 2021

COMPARISON OF FOUR REGIMENS IN NEWLY ADMITTED FEMALE SCHIZOPHRENICS

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000307

7 January 2021

CLINICAL TRIAL OF FLUPHENAZINE ENANTHATE-- A LONG-ACTING INJECTABLE TRANQUILIZER

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000307

7 January 2021

A controlled study of penfluridol in the treatment of chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000307

7 January 2021

A double-blind comparison of fluspirilene and fluphenazine decanoate in schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000307

7 January 2021

A Controlled Trial of Fluphenazine Enanthate in Hospitalized Chronic Schizophrenics

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000307

7 January 2021

A comparative double blind trial of pimozide and fluphenazine in chronic schizophrenia.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000307

7 January 2021

Life Events and Maintenance Therapy in Schizophrenic Relapse

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000307

7 January 2021

Controlled Trial of Depot Fluphenazine in Out-patient Schizophrenics

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000307

7 January 2021

Intermittent pimozide versus fluphenazine decanoate as maintenance therapy in chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000307

7 January 2021

Once weekly pimozide versus fluphenazine decanoate as maintenance therapy in chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000307

7 January 2021

Long-term depot maintenance of chronic schizophrenic out-patients: the seven year follow-up of the Medical Research Council fluphenazine/placebo trial I. Course of illness, stability of diagnosis, and the role of a special maintenance clinic

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000307

7 January 2021

Haloperidol decanoate v. fluphenazine decanoate as maintenance therapy in chronic schizophrenic in-patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000307

7 January 2021

Plasma levels of fluphenazine in patients receiving fluphenazine decanoate. Relationship to clinical response

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000307

7 January 2021

Timing of acute clinical response to fluphenazine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000307

7 January 2021

EFFECT OF PHENOTHIAZINES ON THE THINKING OF ACUTE SCHIZOPHRENICS

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000307

7 January 2021

[Fluphenazine enanthate in long term treatment of psychoses]

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000307

7 January 2021